Clinical Trial Update: A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating CP-690,550 (tofacitinib) with treatment withdrawal and retreatment in moderate to severe chronic plaque psoriasis; trial completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• CP-690,550 (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2014-06-04